SAN DIEGO--(BUSINESS WIRE)--OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced financial results for the quarter ended October 31, 2014.
FINANCIAL RESULTS
For the quarter ended October 31, 2014, OncoSec Medical reported a net loss of $4.1 million, or $0.02 per share, compared to a net loss of $2.1 million, or $0.01 per share, for the same period last year. There were no revenues for quarter ended October 31, 2014 or October 31, 2013.
Help employers find you! Check out all the jobs and post your resume.
